Clinical Trials

NCT Number: NCT03456843 Phase: Phase 2 Trial Summary: This randomized phase II trial studies how well surgical removal of the prostate and antiandrogen therapy with or without docetaxel work in treating men with newly diagnosed prosta – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT03678025 Phase: Phase 3 Trial Summary: This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT03833921 Phase: Phase 2 Trial Summary: The investigators are conducting this study with men that have prostate cancer and are getting standard of care treatment with the drugs abiraterone acetate and prednisone. The stu – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym: APRE

NCT Number: NCT03574571 Phase: Phase 3 Trial Summary: The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helpe – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT03674814 Phase: Phase 1 Trial Summary: The study is an open-label Phase 1 study of the combination of relacorilant with enzalutamide in patients with metastatic castration resistant prostat – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT03682289 Phase: Phase 2 Trial Summary: This phase II trial studies how well Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor AZD6738 works alone or in combination with olaparib or durvalumab in treating par – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT04104893 Phase: Phase 2 Trial Summary: The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) char – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym: CHOMP

NCT Number: NCT04140526 Phase: Phase 1|Phase 2 Trial Summary: This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single a – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym: PRESERVE-001

NCT Number: NCT03971591 Phase: Not Applicable Trial Summary: This study will examine the efficacy of Men Moving Forward (MMF), a four-month community-based lifestyle intervention designed for AA PC survivors. MMF is rooted in the evidence-ba – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym: MMF

NCT Number: NCT00969111 Phase: Not Applicable Trial Summary: The purpose of this study is to see what effects, good and/or bad, proton radiation, and/or conventional radiation and hormonal therapy (if applicable), has on prostate cancer that – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym: